000267 pterygium and_topical_bevacizumab
DESCRIPTION
Bevacizumab in PterigiumTRANSCRIPT
![Page 1: 000267 pterygium and_topical_bevacizumab](https://reader036.vdocuments.us/reader036/viewer/2022082809/556db35ad8b42a875d8b52e1/html5/thumbnails/1.jpg)
PTERYGIUM AND TOPICAL BEVACIZUMAB: A 2 YEAR FOLLOW UP
DR. ADITYA SUDHALKAR,M.S.DR. ANAND SUDHALKAR,M.S.
The authors have no financial interest in this presentation
![Page 2: 000267 pterygium and_topical_bevacizumab](https://reader036.vdocuments.us/reader036/viewer/2022082809/556db35ad8b42a875d8b52e1/html5/thumbnails/2.jpg)
INTRODUCTION
Pterygium: Subconjunctival elastotic degeneration; Can be a cosmetic blemish and/or interfere with vision Excision is the primary treatment modality; recurrence is
often a problem Numerous adjuvants suggested for preventing recurrence,
including:
• Mitomycin C, 5 FU, triamcinolone
• Irradiation**
• Conjunctival autografts Their efficacy however, is variable Bevacizumab has been suggested as an off label use**Effect of subconjunctival bevacizumab on primary pterygiumTeng
CC, Patel NN, Jacobson L. Cornea. 2009 May;28(4):468-70*Topical bevacizumab for corneal limbal neovascularisation to prevent impending recurrence of pterygiumWu PC, Kuo HK, Tai MH, Shin SJ.Cornea. 2009 Jan;28(1):103-4**Strahlenther Onkol. 2009 Dec;185(12):808-14 Vastradis et al.*Med Hypotheses. 2007;69(4):925-7. Bevacizumab as a potential novel adjunct in the management of pterygia
![Page 3: 000267 pterygium and_topical_bevacizumab](https://reader036.vdocuments.us/reader036/viewer/2022082809/556db35ad8b42a875d8b52e1/html5/thumbnails/3.jpg)
PURPOSE:
To determine the efficacy and safety of topical bevacizumab in flurbiprofen as an adjunct to conjunctival autograft in prevention of recurrence of primary pterygium
![Page 4: 000267 pterygium and_topical_bevacizumab](https://reader036.vdocuments.us/reader036/viewer/2022082809/556db35ad8b42a875d8b52e1/html5/thumbnails/4.jpg)
METHODS:
STUDY DESIGN: Prospective Case Series
PATIENTS: 17 consecutive patients of primary pterygium, with :
• No associated systemic or ocular disorder
• No known predisposition to hypersensitivity reactions
TREATMENT: Primary pterygium excision with conjunctival autograft; single surgeon, standardised technique.
POST OPERATIVE REGIMEN(FOR 4 WEEKS-q.i.d.):
• Antibiotic steroid *eye drops
• Bevacizumab(0.3mg/drop), topically with punctal occlusion-5 minutes
• Flurbiprofen eye drops
• Preservative free artificial tears
FOLLOW UPS : Post operative days 1, 7, 30, 90, 180, years 1 and 2.
![Page 5: 000267 pterygium and_topical_bevacizumab](https://reader036.vdocuments.us/reader036/viewer/2022082809/556db35ad8b42a875d8b52e1/html5/thumbnails/5.jpg)
OUTCOME MEASURES:
Recurrence of pterygium
Safety of bevacizumab eye drops administered topically
![Page 6: 000267 pterygium and_topical_bevacizumab](https://reader036.vdocuments.us/reader036/viewer/2022082809/556db35ad8b42a875d8b52e1/html5/thumbnails/6.jpg)
RESULTS:
MEAN AGE: 43.12+/-3.24years(range-35 to 49 years)
GENDER DISTRIBUTION: Males: 10; Females 7
TOPICAL REGIMEN WELL TOLERATED
NO RECURRENCE TILL THE END OF THE FOLLOW -UP PERIOD
• Seven patients complained of foreign body sensation; treated with lubricants
• 2 had dellen formation, resolved with artificial tears
• 1 had hyperemia of the autograft, resolved with flurbiprofen
![Page 7: 000267 pterygium and_topical_bevacizumab](https://reader036.vdocuments.us/reader036/viewer/2022082809/556db35ad8b42a875d8b52e1/html5/thumbnails/7.jpg)
ILLUSTRATIVE CASE:
POST OPERATIVE: AT END OF TWO YEARS
PRE -OPERATIVE
![Page 8: 000267 pterygium and_topical_bevacizumab](https://reader036.vdocuments.us/reader036/viewer/2022082809/556db35ad8b42a875d8b52e1/html5/thumbnails/8.jpg)
DISCUSSION:
Recurrence of pterygium entails further procedures on a patient; excision can leave a scar
Antimetabolites, irradiation not without side effects
Bevacizumab in an off label use has been shown to be effective in prevention of recurrence*
Subconjunctival bevacizumab in immediate post operative period might not prevent neovascularisation which usually occurs later
Multiple subconjunctival* injections potentially hazardous and painful;*Ann Ophthalmol (Skokie). 2010;42 Spec No:28-30. Multiple subconjunctival injections for advanced primary
pterygium*Cornea. 2011 Feb;30(2):127-9 Fallah et al. Intralesional bevacizumab in decreasing pterygium size.
![Page 9: 000267 pterygium and_topical_bevacizumab](https://reader036.vdocuments.us/reader036/viewer/2022082809/556db35ad8b42a875d8b52e1/html5/thumbnails/9.jpg)
DISCUSSION:
Administration of topical therapy(bevacizumab+flurbiprofen) with punctal occlusion did not produce ocular/systemic side effects
Topical therapy gives a prolonged dose of bevacizumab to the autograft
None of the patients showed a recurrence till the end of follow up period
Steroids not a confounding factor as they have not shown to significantly alter recurrence rates*~*Cornea. 2010 Feb;29(2):141-5, Comparison of recurrence rates….Kandavel et al
~Ann Ophthalmol. 1985 Jan;17(1):92-5. Pterygium: clinical classification and management in Virgin Islands. Anduze et al.~East Afr Med J. 1992 Sep;69(9):490-3. Post-operative management of pterygium in Jos, Nigeria--comparison of antibiotics, steroids and opticrom
![Page 10: 000267 pterygium and_topical_bevacizumab](https://reader036.vdocuments.us/reader036/viewer/2022082809/556db35ad8b42a875d8b52e1/html5/thumbnails/10.jpg)
REFERENCES:
Pterygium. Etiology, clinical aspects and novel adjuvant therapies].Heindl LM, Cursiefen C.Ophthalmologe. 2010 Jun;107(6):517-20, 522-4
Safety and efficacy of intraoperative 5-fluorouracil infiltration in pterygium treatment].
Vlezi VG, et al. Arq Bras Oftalmol. 2009 Mar-Apr;72(2):169-73.
Comparative Study of Different β-Radiation Doses for Preventing Pterygium Recurrence.
Yamada T et al. Int J Radiat Oncol Biol Phys. 2010 Oct
Results of treatment with topical mitomycin C 0.02% following excision of primary pterygium. Rachmiel R et al.Br J Ophthalmol. 1995 Mar;79(3):233-6
Postoperative subconjunctival corticosteroid injection to prevent pterygium recurrence.
Paris Fdos et al.Cornea. 2008 May;27(4):406-10
Dev Ophthalmol. 2010;46:133-9. Scholl et al. Anti vascular growth factors in anterior segment disease
Cornea. 2009 May;28(4):468-70. Teng et al. Effect of subconjunctival bevacizumab on primary pterygium
![Page 11: 000267 pterygium and_topical_bevacizumab](https://reader036.vdocuments.us/reader036/viewer/2022082809/556db35ad8b42a875d8b52e1/html5/thumbnails/11.jpg)
LIMITATIONS:
Small sample size
No control group
Further studies will be required
![Page 12: 000267 pterygium and_topical_bevacizumab](https://reader036.vdocuments.us/reader036/viewer/2022082809/556db35ad8b42a875d8b52e1/html5/thumbnails/12.jpg)
CONCLUSION
Topical Bevacizumab appears to be safe and effective in preventing pterygium recurrence.